ALEC Quote, Financials, Valuation and Earnings

Lifecore Biomedical, Inc. has a net margin of -1063.41% compared to Alector, Inc.'s net margin of -32.12%. Alector, Inc.'s return on equity of -114.8% beat Lifecore Biomedical, Inc.'s return on equity of -70.33%.

Alector, Inc. has a consensus price target of $2.05, signalling upside risk potential of 69.42%. On the other hand Lifecore Biomedical, Inc. has an analysts' consensus of $8.75 which suggests that it could grow by 12.61%. Given that Alector, Inc. has higher upside potential than Lifecore Biomedical, Inc., analysts believe Alector, Inc. is more attractive than Lifecore Biomedical, Inc..

Alector, Inc. has a beta of 0.667, which suggesting that the stock is 33.287% less volatile than S&P 500. In comparison Lifecore Biomedical, Inc. has a beta of 0.599, suggesting its less volatile than the S&P 500 by 40.067%.

Alector, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lifecore Biomedical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alector, Inc. pays -- of its earnings as a dividend. Lifecore Biomedical, Inc. pays out -- of its earnings as a dividend.

Alector, Inc. quarterly revenues are $3.3M, which are smaller than Lifecore Biomedical, Inc. quarterly revenues of $31.1M. Alector, Inc.'s net income of -$34.7M is lower than Lifecore Biomedical, Inc.'s net income of -$10M. Notably, Alector, Inc.'s price-to-earnings ratio is -- while Lifecore Biomedical, Inc.'s PE ratio is 133.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alector, Inc. is 1.76x versus 2.09x for Lifecore Biomedical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -1063.41% compared to Alector, Inc.'s net margin of -255.85%. Alector, Inc.'s return on equity of -114.8% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Alector, Inc. has a consensus price target of $2.05, signalling upside risk potential of 69.42%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -22.02%. Given that Alector, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Alector, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Alector, Inc. has a beta of 0.667, which suggesting that the stock is 33.287% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Alector, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Alector, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Alector, Inc. quarterly revenues are $3.3M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Alector, Inc.'s net income of -$34.7M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Alector, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alector, Inc. is 1.76x versus 2.12x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -1063.41% compared to Alector, Inc.'s net margin of --. Alector, Inc.'s return on equity of -114.8% beat Palatin Technologies's return on equity of --.

Alector, Inc. has a consensus price target of $2.05, signalling upside risk potential of 69.42%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Alector, Inc., analysts believe Palatin Technologies is more attractive than Alector, Inc..

Alector, Inc. has a beta of 0.667, which suggesting that the stock is 33.287% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Alector, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alector, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Alector, Inc. quarterly revenues are $3.3M, which are larger than Palatin Technologies quarterly revenues of --. Alector, Inc.'s net income of -$34.7M is higher than Palatin Technologies's net income of --. Notably, Alector, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alector, Inc. is 1.76x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -1063.41% compared to Alector, Inc.'s net margin of --. Alector, Inc.'s return on equity of -114.8% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Alector, Inc. has a consensus price target of $2.05, signalling upside risk potential of 69.42%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 2797.35%. Given that Theriva Biologics, Inc. has higher upside potential than Alector, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Alector, Inc..

Alector, Inc. has a beta of 0.667, which suggesting that the stock is 33.287% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

Alector, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alector, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Alector, Inc. quarterly revenues are $3.3M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Alector, Inc.'s net income of -$34.7M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Alector, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alector, Inc. is 1.76x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.